Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01019889

Acronym

ESYUI

Enrollment

480

Registered

2009-11-25

Start date

2008-09-30

Completion date

2009-07-31

Last updated

2012-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Respiratory Tract Infections

Keywords

upper respiratory tract infections, herbal medicine

Brief summary

The purpose of this study is to determine whether Socheongryong-tang (SCRT) and Yeongyopaedok-san (YPS) are effective in the treatment of upper respiratory tract infection.

Detailed description

Upper respiratory tract infections (URTIs) are the most prevalent disease of human beings, it incur a significant health burden on populations in terms of human suffering and economic losses. Usually, antibiotic therapy is not helpful since most infections are virally induced. Over 200 serologically different viral types are responsible for human URTIs, so that preventions of URTIs including vaccination are impassable. SCRT and YPS are widely used to treat the respiratory disease. The objective of this study is to determine the efficacy of SCRT and YPS in symptomatic relief of patients with URTIs.

Interventions

DRUGSCRT

4 capsules,three times daily, for 7days or within symptom disappearance

DRUGYPS

4 capsules, three times daily, for 7days or within symptom disappearance

DRUGPlacebo

4 capsules, three times daily, for 7days or within symptom disappearance

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* 18\ 60 years old * Clinical diagnosis of common cold * Occurring no longer than 48 hours before enrollment * Presented with runny nose, sore throat, plugged nose, scratchy throat, cough, hoarseness, headache, muscle ache (runny nose, sore throat and at least 1 of others or 1 of runny nose, sore throat and at least 3 of others)

Exclusion criteria

* Allergic rhinitis, asthma, COPD, sinusitis (2 and more recurrence per year), septal deviation, anatomical otitis media, exudative pharyngitis * Received antihistamines, NSAIDs, corticosteroids, antibiotics, decongestants * Hepatic cancer, liver cirrhosis, renal failure, congestive heart failure * Pregnant or lactation

Design outcomes

Primary

Measure	Time frame
Changes of score daily measured by WURSS-K before, during and after treatment	daily (7 days)

Secondary

Measure	Time frame
Time of symptom disappearance	daily
Changes of score daily measured by WURSS-K before, during and after treatment in pattern identification	daily (7days)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026